bioMerieux released Q3 FY16 trading results in line with street estimates. Total revenue increased by 9.1% at CER (vs Q3 15: +8.8%), fuelled by strong growth in the clinical applications segment (+9.8% vs Q3 15: +7.9%; c.81% of Q3 16 sales). Within the segment, the growth in the molecular biology business accelerated to +48.0% (vs Q3 15: +31.7%; c.16% of Q3 16 sales), led by strong demand for instruments in the FilmArray business line (+78.0% yoy). The strong performance continued in the micr
03 Nov 2016
FilmArray continues to fuel the growth momentum
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FilmArray continues to fuel the growth momentum
bioMerieux released Q3 FY16 trading results in line with street estimates. Total revenue increased by 9.1% at CER (vs Q3 15: +8.8%), fuelled by strong growth in the clinical applications segment (+9.8% vs Q3 15: +7.9%; c.81% of Q3 16 sales). Within the segment, the growth in the molecular biology business accelerated to +48.0% (vs Q3 15: +31.7%; c.16% of Q3 16 sales), led by strong demand for instruments in the FilmArray business line (+78.0% yoy). The strong performance continued in the micr